Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
In brief
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.
Key facts
- Study ID
- NCT05098132
- Run by
- Synthekine
- People needed
- 364
- Starts
- 2022-01-25
- Expected to finish
- 2029-01-01
- Last updated by the study team
- 2026-07-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago — Chicago, Illinois, United States (enrolling)
- Beverly Hills Cancer Center — Beverly Hills, California, United States (enrolling)
- Providence Medical Foundation — Fullerton, California, United States (enrolling)
- St. James Hospital — Dublin, Ireland (enrolling)
- Beaumont Hospital — Dublin, Ireland (enrolling)
- University Hospital Galway — Galway, Ireland (enrolling)
- Hospital Quirón Barcelona — Barcelona, Spain (enrolling)
- START Rioja — Logroño, Spain (enrolling)
- MD Anderson — Madrid, Spain (enrolling)
- Hospital Universitario Ramon y Cajal — Madrid, Spain (enrolling)
- Hospital Regional de Málaga — Málaga, Spain (enrolling)
- Clinica Universidad de Navarra - Pamplona — Pamplona, Spain (enrolling)
- Cedars Sinai — Los Angeles, California, United States (enrolling)
- Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States (enrolling)
- UCLA Hematology/Oncology - Santa Monica — Santa Monica, California, United States (enrolling)
- Yale New Haven Hospital, Yale Cancer Center — New Haven, Connecticut, United States (enrolling)
- Georgetown University — Washington D.C., District of Columbia, United States (enrolling)
- Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
- University of Arizona Cancer Center — Tucson, Arizona, United States (enrolling)
- University of Maryland — Baltimore, Maryland, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- HealthPartners Cancer Center at Regions Hospital — Saint Paul, Minnesota, United States (enrolling)
- Northwell Health — Lake Success, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.